New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:07 EDTXNCRXencor's asthma candidate shows posive results in preclinical study
Xencor will present preclinical data comparing activity of XmAb7195 to omalizumab in reducing IgE, a protein responsible for triggering disease activity in asthma and other allergic disorders. The study supports future studies in human clinical trials. The results of the study found that after a single 5 mg/kg intravenous dose of XmAb7195 or omalizumab in chimpanzees, XmAb7195 reduced free IgE to at least 10-fold lower levels than omalizumab. Similar to its effects in humans, omalizumab increased total IgE. In contrast, XmAb7195 rapidly depleted total IgE below quantifiable levels within 1 hour.
News For XNCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 12, 2014
11:17 EDTXNCRLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 11, 2014
15:43 EDTXNCRLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 10, 2014
16:14 EDTXNCRXencor maintains 2014 year end cash, equivalents view approximately $54M
Subscribe for More Information
16:12 EDTXNCRXencor reports Q3 EPS (20c), consensus (19c)
Reports Q3 revenue $800,000, consensus $1.17M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use